Semaglutide, the active ingredient in Ozempic and Wegovy, just did something in old mice that no weight-loss drug is supposed to do: it appeared to slow the biology of ageing and extend lifespan. The catch is that it did so in a way that only partly overlaps with simply eating less.
The finding comes from a new paper in Nature (2026) from researchers at UC Berkeley, with collaborators at the University of Copenhagen and the National Institute on Aging. It is a mouse study, and it should be read as one. Still, it gives a possible mechanistic framework for why GLP-1 drugs seem to help far beyond blood sugar and body weight.
What the researchers actually did
The team treated 20-month-old female C57BL/6 mice with semaglutide for three months. That is late life for a laboratory mouse, so the intervention was not started in youth or middle age.
According to the abstract, the treatment:
- improved physiological function
- attenuated hallmarks of ageing
- modulated nutrient sensors and conserved genetic regulators of ageing
When treatment continued, lifespan was extended. The abstract does not give the size of the effect, so this article does not quote one.
The calorie restriction comparison
Calorie restriction (CR) is the most reliable lifespan-extending intervention in laboratory animals. It slows ageing and lowers the burden of many age-related diseases. Because GLP-1 drugs suppress appetite, an obvious question is whether semaglutide just works as CR with a syringe.
The researchers tested this directly with a longitudinal comparison against matched calorie restriction. The results were nuanced:
- Overlap with CR: Semaglutide preserved baseline function and reproduced many of CR's functional benefits by attenuating age-associated decline.
- Where it looked different: In exploratory drive, spatial memory and glucose control, semaglutide-treated mice showed improvements above baseline and more favourable trajectories than CR.
The authors describe GLP-1R activation as a "calorie restriction mimetic" that also shows effects "beyond those attributable to reduced calorie intake." In other words, eating less probably explains part of the story but not all of it.
Why this matters
GLP-1 medicines have shown benefits beyond glucose and weight control, and the abstract notes that the biological basis of these broader effects is poorly understood. This study offers a candidate explanation: the drug may engage the same nutrient-sensing and ageing-regulatory pathways that CR does. If so, some of the broad benefits seen in patients could reflect a slowing of ageing processes rather than a collection of unrelated side benefits.
That is a hypothesis grounded in mouse data, not a settled mechanism in people.
What this does not mean for people
The limits matter here:
- It is animal research. Mouse lifespan results often fail to translate to humans, and this study does not tell us whether semaglutide extends human lifespan.
- Only female mice were reported. The title and abstract specify females, so the findings should not be assumed to apply to males, let alone to men.
- One strain, one starting age. The work used C57BL/6 mice started at 20 months.
- Late-life start in mice is not a human equivalent. Mapping mouse months onto human years is imprecise.
- Possible conflict of interest. The Regents of the University of California filed a patent application on GLP-1 receptor agonists for healthy ageing. That does not invalidate the work, but it is worth knowing.
For people already taking a GLP-1 drug for diabetes or obesity, the study is not evidence that they are slowing their own ageing. It is also not a reason to start or stop a prescription.
Practical takeaways: dose, timing and who it's for
People reasonably want actionable guidance from a headline like this. The honest answer is that the paper does not provide it.
- Dose: The abstract gives no dosing information, and a mouse dose cannot be converted into a human regimen by guesswork. Nothing here supports an "anti-ageing dose" of semaglutide.
- Timing: In mice, treatment began late in life (20 months) and ran for three months before continuing for the lifespan analysis. That is a study design, not a recommendation for when humans should begin anything.
- Who it's for: Semaglutide is currently prescribed for type 2 diabetes and obesity. Nothing in this study establishes it as a longevity therapy for healthy people, and the researchers' own framing is that this is a mechanistic framework, not a clinical protocol.
The practical message for now is to treat GLP-1 therapy as a medical decision made with a clinician, based on established indications, and to regard longevity as a possible bonus that still needs human trials.
What to watch next
The key next steps are replication, testing in male mice and other strains, and, most importantly, human studies designed to measure ageing outcomes rather than weight or glucose. The finding that semaglutide outperformed matched CR on exploratory drive, spatial memory and glucose control also deserves follow-up. It hints that GLP-1 receptor activation may reach biology that simple calorie reduction does not.
For now, this is a strong preclinical signal in a top journal, and a reminder that the drugs reshaping obesity treatment may be touching something more fundamental than appetite.
Source: Feng Y, et al. "Late-life semaglutide treatment slows ageing and extends lifespan in female mice." Nature 2026;657(8131):469-476. doi:10.1038/s41586-026-10940-7.